As the domestic pharmaceutical and biotech industries enhance decentralized clinical trials (DCT) to overcome limitations of traditional trial methods, JNPMEDI is showcasing its technological prowess.
According to the company on the 25th, the confirmation of the DCT for digital therapy 'WELT-I' serves as a prominent case demonstrating their technological capabilities and expertise. The company has been evaluated as a leading enterprise in the domestic DCT field, driving innovation in digital clinical trials.
JNPMEDI's clinical data management solution 'Maven Clinical Cloud' supports efficient patient data collection, analysis, and trial management for digital clinical trials. Emphasizing enhanced trial efficiency through remote monitoring and real-time data tracking, the platform facilitates medical research and innovation with rich data and analysis.
Recently, they launched the pharmaceutical safety management solution 'Maven Safety'. Maven Safety provides three solutions: △Optimized regulatory reporting △Collaboration-based safety data management △Enhanced productivity in clinical research. A JNPMEDI official stated, "Continuing our research and development efforts, we aim to continuously introduce solutions optimized for clinical trial sites and lead the growth of the domestic DCT market."
Previously in July, JNPMEDI signed a memorandum of understanding (MOU) with Kangbuk Samsung Hospital for the establishment of a patient-centered smart clinical trial center, highlighting their crucial role in the digital transformation and globalization of domestic clinical research.
Moreover, they participated in the 'New Technology Development Research Consortium for Decentralized Clinical Trials' centered at Seoul National University Hospital. The consortium, consisting of Seoul National University Hospital and 7 other hospitals, along with 10 healthcare-related companies, is conducting research and development on core technologies of decentralized clinical trials, including remote monitoring.
As the domestic pharmaceutical and biotech industries enhance decentralized clinical trials (DCT) to overcome limitations of traditional trial methods, JNPMEDI is showcasing its technological prowess.
According to the company on the 25th, the confirmation of the DCT for digital therapy 'WELT-I' serves as a prominent case demonstrating their technological capabilities and expertise. The company has been evaluated as a leading enterprise in the domestic DCT field, driving innovation in digital clinical trials.
JNPMEDI's clinical data management solution 'Maven Clinical Cloud' supports efficient patient data collection, analysis, and trial management for digital clinical trials. Emphasizing enhanced trial efficiency through remote monitoring and real-time data tracking, the platform facilitates medical research and innovation with rich data and analysis.
Recently, they launched the pharmaceutical safety management solution 'Maven Safety'. Maven Safety provides three solutions: △Optimized regulatory reporting △Collaboration-based safety data management △Enhanced productivity in clinical research. A JNPMEDI official stated, "Continuing our research and development efforts, we aim to continuously introduce solutions optimized for clinical trial sites and lead the growth of the domestic DCT market."
Previously in July, JNPMEDI signed a memorandum of understanding (MOU) with Kangbuk Samsung Hospital for the establishment of a patient-centered smart clinical trial center, highlighting their crucial role in the digital transformation and globalization of domestic clinical research.
Moreover, they participated in the 'New Technology Development Research Consortium for Decentralized Clinical Trials' centered at Seoul National University Hospital. The consortium, consisting of Seoul National University Hospital and 7 other hospitals, along with 10 healthcare-related companies, is conducting research and development on core technologies of decentralized clinical trials, including remote monitoring.